



Forbion analysis on European biotech landscape published in Nature Biotechnology

Revealing large differences in the startup scene across Europe and highlighting the underlying causal factors

Naarden, The Netherlands, and Munich, Germany, April 2, 2019 Forbion, a leading European life sciences venture capital firm, today announces that its analysis on the European biotech start-up landscape is being published in Nature Biotechnology.

The study shows large differences in biotechnology startup formation among the various European nations. Factors contributing positively to a successful biotechnology start-up ecosystem include a robust, government-funded science base, but the analysis also emphasizes the need for strength in both financial (i.e. venture capital) and human capital, and for biomedical patent activity. (<http://dx.doi.org/10.1038/s41587-019-0076-4>)

The article follows a series of earlier publications by Forbion in Nature biotechnology, including *Venturing Across the Atlantic*, (<https://www.nature.com/articles/nbt.3712>) *Acquiring Orphans* (<https://www.nature.com/articles/nbt.2836>), and *Building for big pharma* (<https://www.nature.com/bioent/2013/130301/full/bioe.2013.3.html>). These articles represent primary research on topics that are of interest to biotech entrepreneurs, investors and policy makers. Forbion believes that fundamental science drives biomedical innovation, and aspires to help scientists and biotech entrepreneurs to advance science into the development of drugs that have a genuine impact on the future of medicine.

ENDS

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion's investment team has built an impressive performance track record since the late nineties with successful investments in over 60 companies. Forbion manages well over EUR 1 billion across ten funds. Forbion is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect health and well-

being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI) facilities and AMUF facilities and the KfW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion operates a joint venture with BGV, the manager of seed and early stage funds focused on Benelux and Germany. For more information, please visit: www.forbion.com.

Contacts

Forbion contact:

Rogier Rooswinkel

Partner

P: +31 (0) 35 699 3010

E: rogier.rooswinkel@forbion.com